Alexandru Bacita | Co-Founder & COO, The Cat Health Company
Cats are living longer, but the drugs for age-related disease have not kept pace. The Cat Health Company, a clinical-stage biotech, has three drugs in trials and 11 more preclinical candidates, and has out-licensed its first therapeutic. Co-founder and COO Alexandru Bacita explains why cats compress the drug-development loop, how the company targets muscle loss and kidney disease first, and why the route to longevity runs through veterinarians and pharma partners.

Cats are living longer, but many age-related diseases still have limited treatment options. The Cat Health Company thinks that can change.
We spoke with Alexandru Bacita, co-founder and COO of The Cat Health Company, a clinical-stage biotech using machine learning to develop medicines for age-related diseases in cats. Bacita previously worked in human drug discovery before turning his attention to feline health.
In less than two years, the company says it has moved three drugs into clinical trials, built a pipeline of 11 more preclinical candidates, and out-licensed its first therapeutic. Its most advanced programs target age-related muscle loss and chronic kidney disease.
But the ambition goes beyond cats. Because cats naturally develop many of the same diseases of aging seen across mammals, the company believes what it learns could eventually help answer a much bigger question: how far can we extend healthy life?
Give us a short intro. What is The Cat Health Company, and what are you ultimately trying to accomplish?
We’re a clinical-stage biotech using machine learning to develop medicines for the diseases of old age in cats. In under two years, we’ve produced clinical-stage drugs, seen treatments make a real difference in very sick cats, and out-licensed our first therapeutic to pharma. Ultimately, we want to go beyond nine lives and then, beyond known limits for all species.
Other Interviews
More conversations with founders, operators, and investors building the future of pet care.



